Brief: Cipla Clarifies On Report USFDA Issues Form 483 Observations On Pharmathen
07/01/2026 13:37
Jan 7 (Reuters) - Cipla Ltd CIPL.NS: CLARIFIES ON REPORT USFDA ISSUES FORM 483 OBSERVATIONS ON PHARMATHEN PHARMATHEN MANUFACTURES LANREOTIDE INJECTION FOR CIPLA USA PHARMATHEN IS OUR SUPPLY PARTNER, MANUFACTURING LANREOTIDE INJECTION FOR CIPLA USA INC PHARMATHEN RECEIVED NINE INSPECTIONAL OBSERVATIONS FROM USFDA Source text: ID:nBSE2qbc0D Further company coverage: CIPL.NS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cipla
See all newsIndian pharma stocks up on report US taps drugmakers for critical cancer drug
India's Cipla jumps after Citi sees near-term positive triggers for earnings
Factbox: Global drugmakers invest billions to boost US presence
India raises price cap on cancer drugs to tackle shortage
Brief: Cipla Says USFDA Classified Verna Manufacturing Facility Inspection As Voluntary Action Indicated